← All candidates
53 insider filings on record.
53 filings on record.
RIGLRIGEL PHARMACEUTICALS INC
NasdaqGS · Healthcare · $858.53M
$44.36
53 insider filings on record.
None of them an open-market buy in the last year.
No price data yet — the yfinance scanner hasn't produced bars for RIGL.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$858.53M
Float
14.8M
79% public
Short % float
Pro
Price / profit
2.7
Price / future profit
9.3
Price / sales
3.1
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
48 more transactions on Pro →Context
Wall St
$54.20 avg target
+22.2% vs today · 5 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26$0.44 act−$0.43
Q4 '25$1.12 act−$0.08
Q3 '25$1.46 act+$0.52
Q2 '25$3.28 act+$1.87
Coverage
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE StorySimply Wall St. · 05-21Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, PfizerBenzinga · 05-15Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?Simply Wall St. · 05-14Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap PersistsSimply Wall St. · 05-13
The file stays open
53 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice